SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial

Inclusion Criteria:

1. Males or females aged 18 to 85 years;
2. According to the Key points for diagnosis of various major cerebrovascular diseases inChina 2019 and combined with the experience of clinicians, patients with ischemicstroke were diagnosed;
3. From "the last time that looks normal" to the beginning of drug treatment ≤ 48 hours.When the onset time of symptoms can not be accurately obtained after awakening strokeor due to aphasia, disturbance of consciousness and other reasons, the final time ofnormal performance of patients should be taken as the criterion.
4. First onset of ischemic stroke or prestroke with mRS of 0 or 1;
5. A National Institutes of Health Stroke Scale (NIHSS) score between 6 and 20, and atotal score of upper and lower limbs ≥2 on motor deficits;
6. Capable of understanding the purpose and risk of the study and has signed, in writing,the informed consent form (ICF). If the subject is not capable of this at the time ofenrollment, a legally authorized representative (LAR) will provide written informedconsent in accordance with all regulations.

Exclusion Criteria:

1. Serious disturbance of consciousness (NIHSS 1a ≥2 score);
2. Based on the opinion of the Investigator, the posterior circulation symptoms likeataxia in stroke patients are caused by posterior circulation ischemia, such asbrainstem or cerebellum;
3. Neuroimaging (CT/MRI) revealed intracranial hemorrhagic diseases (such as cerebralhemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, ventricularhemorrhage, traumatic cerebral hemorrhage, etc.);
4. Rapidly improving or resolving symptoms, suggesting a possible transient ischemicattack (TIA) rather than a qualifying stroke;
5. Subjects who are ready to undergo or have undergone intravenous thrombolysis, orendovascular therapy in 90 days from onset;
6. Renal insufficiency: Serum creatinine > 2.5 times the upper limit of normal value, orother known serious renal insufficiency diseases;
7. Liver function damage: ALT and AST > 2.5 times the upper limit of normal value, orother known liver diseases such as acute and chronic hepatitis, cirrhosis, etc.;
8. Poorly controlled hypertension, with systolic blood pressure (≥ 180 mmHg) and/ordiastolic blood pressure ( ≥110 mmHg);
9. Subjects with heart rate < 40 beats/min and/or heart rate > 120 beats/min; 2-degree or 3-degree cardiac block without pacemaker or other malignant arrhythmia; acutemyocardial infarction or interventional therapy in the past month, patients with heartfailure (according to NYHA grade III-IV);
10. Patients with status epilepticus who are unable to cooperate or unwilling to cooperatedue to other organic mental disorders and moderate or severe cognitive impairment;
11. Subjects with malignant tumors, serious diseases of the blood, digestive or othersystems or hemophilia and the expected survival time is not more than 3 months;
12. Female subjects who are pregnant, lactating/breast-feeding, or plan to becomepregnant;
13. Allergic constitution, or allergic to experimental drugs, analogous drugs or basictreatment drugs;
14. Received treatment with any other investigational drug within 30 days before Baseline,or is currently participating in another clinical study;
15. Any other reasons that, in the opinion of the investigator, make the subjectunsuitable for enrollment.